Drugs / Johnson & Johnson
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06360744 | Jul 2021 → Dec 2023 | COVID-19 | Jens D Lundgren, MD | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05019456 | Mar 2021 → Dec 2025 overdue | COVID-19, influenza | University of Arizona | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Johnson & Johnson | “Healthy physically active participants completed a 20-min bout of graded cycling exercise at intensities corresponding to 50%, 60%, 70%, and 80% of the predetermined V̇O2max...” PMID 34882029 ↗ Dec 2021 |
| Known as | Janssen | “SARS-CoV-2 vaccine from Johnson \& Johnson/Janssen” NCT06360744 ↗ |
| Modality | Vaccine | “SARS-CoV-2 vaccine from Johnson \& Johnson/Janssen” NCT06360744 ↗ |